Abstract: This invention provides a bacterin comprising a virulent Mycoplasma hyopneumoniae isolate, inactivated with binary ethyleneimine, in an amount effective to immunize a swine against infection by Mycoplasma hyopneumoniae and a suitable physiologically acceptable carrier. The invention also provides a method of producing this bacterin. The invention further provides a method of inactivating a virulent strain of Mycoplasma hyopneumoniae by contacting the Mycoplasma hyopneumoniae with binary ethyleneimine. Finally, the invention also provides a method of immunizing swine against infection by Mycoplasma hyopneumoniae comprising administering to the swine a dose of the bacterin so as to immunize the swine.
Abstract: A immunoadjuvant soluble phosphazene polyelectrolyte is disclosed. In one embodiment, the polymeric adjuvant is an poly(organophosphazene) with (i) ionized or ionizable pendant groups that contain, for example, carboxylic acid, sulfonic acid, or hydroxyl moieties, and (ii) pendant groups that are susceptible to hydrolysis under the conditions of use, to impart biodegradability to the polymer.
Type:
Grant
Filed:
July 12, 1993
Date of Patent:
October 8, 1996
Assignees:
Massachusetts Institute of Technology, Virus Research Institute, The Penn State Research Foundation
Inventors:
Harry R. Allcock, Alexander K. Andrianov, Robert S. Langer, Karyn B. Visscher
Abstract: The present invention provides cleavable conjugates whose linkers contain a labile bond that is cleavable under a variety of mild conditions, including weakly acidic. Since the agent may be bonded directly to the linker, cleavage can result in release of native agent. The invention also provides methods for producing cleavable conjugates. Preferred agents include drugs, toxins, biological response modifiers, radiodiagnostic compounds, radiotherapeutic compounds, and derivatives thereof. The targeting molecule employed in the invention may be an intact molecule, a fragment thereof, or a functional equivalent thereof. In a particularly preferred embodiment, the targeting molecule is a monoclonal antibody directed towards a tumor-associated antigen in man. The invention further provides methods for delivering to the cytoplasm of a target cell an agent free of its targeting molecule carrier.
Type:
Grant
Filed:
May 13, 1994
Date of Patent:
October 8, 1996
Assignee:
NeoRx Corporation
Inventors:
Mark D. Hylarides, Ananthachari Srinivasan, Jeffrey N. Fitzner, Vivekananda M. Vrudhula
Abstract: A phospholipid derivative of the following formula (I): ##STR1## wherein A is a residue of a phospholipid having a phosphatidylethanolamine moiety, and B is a linking group having a polyalkylene glycol moiety.
Abstract: Conjugates of general formula 1:[A--O--W--Z].sub.a --T 1wherein the moiety A--O-- is the residue of drug of formula A--O--H in which --O--H is a primary or secondary hydroxyl group; a is an integer of from 1 to 30; W is a group of general formula 2: ##STR1## wherein b is an integer of from 1 to 4, B represents a C.sub.1 -C.sub.3 alkylene group and R.sub.1 and R.sub.2 each independently represent hydrogen, halogen, alkyl, phenyl or substituted phenyl; Z is a spacer group and T is a carrier moiety.
Type:
Grant
Filed:
October 25, 1994
Date of Patent:
August 20, 1996
Assignee:
Farmitalia Carlo Erba S.r.l.
Inventors:
Francesco Angelucci, Laura Bersani, Michele Caruso, Marina Ripamonti, Daniela Ruggieri, Antonino Suarato
Abstract: The invention includes methods for inhibiting retroviral infections such as HIV. The methods of this invention involve the use of certain fragments of fibronectin and such fragments conjugated to carrier molecules such as ovalbumin to inhibit retroviral infections. The invention also includes novel proteins which comprise fibronectin fragments covalently linked to carrier proteins.
Type:
Grant
Filed:
August 16, 1994
Date of Patent:
August 13, 1996
Assignees:
The United States of America as represented by the Department of Health and Human Services, Reagents of the University of Minnesota
Inventors:
Sharon M. Wahl, James B. McCarthy, Leo T. Furcht
Abstract: Novel nitroaromatic compounds and immunogenic conjugates comprising a novel nitroaromatic compound and a carrier protein are disclosed. The invention further presents monoclonal antibodies highly specific for the claimed nitroaromatic compounds, the compounds' protein conjugates, the compounds' reductive byproducts, and adducts formed between the compounds and mammalian hypoxic cell tissue proteins. The invention is further directed to methods for detecting tissue hypoxia using immunohistological techniques, non-invasive nuclear medicinal methods, or nuclear magnetic resonance. Diagnostic kits useful in practicing the methods of claimed invention are also provided.
Type:
Grant
Filed:
August 4, 1994
Date of Patent:
July 30, 1996
Assignees:
The Trustees of the Univ. of Pennsylvania, The University of Rochester
Abstract: Methods and compositions are described for modulating trafficking of leukocytes to endothelial cells involving the binding of homing receptors and addressins. Particularly, compositions are provided which can inhibit the interaction between the homing receptor and addressin or provide for directing specific molecules associated with diagnosis or treatment, where the molecules bind to the addressins.
Type:
Grant
Filed:
December 19, 1991
Date of Patent:
July 23, 1996
Assignee:
The Board of Trustees for the Leland Stanford Junior Univ.
Inventors:
Eugene C. Butcher, Philip R. Streeter, Ellen L. Berg
Abstract: Disclosed is a method for the inhibition of binding of a ligand to an RNA, the inhibition being mediated by a small organic molecule which binds to the RNA, thereby inhibiting ligand binding. A preferred class of small organic molecules are the 2-deoxystreptamine (2-DOS) aminoglycosides. Disclosed herein are members of the 2-DOS class that are useful for the inhibition of binding of Rev to an RNA containing an RRE. In an HIV infected cell, a consequence of the inhibition of the ability of Rev to bind to the RRE in HIV encoded transcripts is inhibition of HIV replication.
Type:
Grant
Filed:
September 24, 1993
Date of Patent:
July 9, 1996
Assignee:
University Of Massachusetts Medical Center
Inventors:
Michael R. Green, Maria L. Zapp, Seth Stern
Abstract: The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.
Abstract: Methods are provided for detecting and/or treating lesions in a patient. The methods use a targeting composition comprised of a biotin and targeting protein conjugate or an avidin and targeting protein conjugate; optionally, a clearing composition comprised of avidin, when the targeting composition is a biotin conjugate, or biotin, when the targeting composition is a avidin conjugate; a detection or therapeutic composition comprised of a conjugate of avidin or biotin with a targeting protein and detection or therapeutic agent; and, optionally, another detection or therapeutic composition comprised of avidin or biotin conjugated to a detection or therapeutic agent. Compositions and kits useful in the methods are also provided.
Abstract: Polymeric compounds comprising subunits of the following formulas ##STR1## wherein R.sub.1, X, x, y, z, x', y' and z' are as defined in the application. The polymeric compounds are capable of stimulating the immune response system of animals, including humans. The polymeric compounds are useful also in the manufacture of medicaments, including vaccines, for the prophalaxis and treatment of conditions requiring an enhanced immune response.
Type:
Grant
Filed:
September 10, 1993
Date of Patent:
April 2, 1996
Assignee:
Petrovax, L.L.C.
Inventors:
Nekrasov A. Vasilevich, Puchkova N. Grigorjevna, Ataullakhanov R. Inojativich, Petrov R. Victorovich, Khaitov R. Musaevich, Ivanova A. Sergeevna
Abstract: Pro-cytotoxic drug conjugates for anticancer therapy comprising a homing agent first moiety, a spacer molecule second moiety covalently linked to the homing agent, and a third moiety covalently linked to the second moiety consisting of a pro-cytotoxic drug that is non-toxic extracellularly but that, after internalization of the conjugate by proliferating tumor cells, is metabolized by one or more endogenous intracellular enzymes to a cytotoxic metabolic product, so that cell growth is arrested or the cells killed. Preferred procytotoxic drugs are carboxyphosphamide or carboxyisophosphamide.
Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.
Abstract: An immunoadjuvant soluble polyphosphazene polyelectrolyte is disclosed. In one embodiment, the polymeric adjuvant is an poly(organophosphazene) with (i) ionized or ionizable pendant groups that contain, for example, carboxylic acid, sulfonic acid, or hydroxyl moieties, and (ii) pendant groups that are susceptible to hydrolysis under the conditions of use, to impart biodegradability to the polymer.
Type:
Grant
Filed:
July 11, 1994
Date of Patent:
February 27, 1996
Assignee:
Virus Research Institute
Inventors:
Alexander K. Andrianov, Sharon A. Jenkins, Lendon G. Payne, Bryan E. Roberts
Abstract: Peptides which present an epitope substantially similar to the activation site region epitope of apolipoprotein(a) are provided. Antibodies raised against such peptides bind to apolipoprotein(a). Such antibodies and peptides, as well as peptide constructs for immunization are provided. Also provided are monoclonal antibodies and hybridomas, polyclonal serum, assays, diagnostic systems in kit form, chromatographic methods and materials, and synthetic secondary standards. Therapeutic compositions and methods are also provided.
Abstract: A method for forming a controlled release polymeric substrate is provided by contacting a polymeric substrate with a liquid mixture containing a cross-linking agent at least partially soluble therein comprising water and an organic liquid, for a period of time and at a temperature and concentration of the agent sufficient for the agent to penetrate the substrate to form cross-linking bridges in the substrate in a decreasing concentration gradient beneath the surface.
Abstract: Processes for the killing of cancerous B cells, and particularly chronic lymphocytic leukemia (CLL) cells are disclosed. In one process, cancerous B cells that do not proliferate when contacted with an immune response-enhancing agent are contacted with an amount of such an agent sufficient to cause peripheral CLL cells to undergo blast transformation and proliferation. The contacted cells are then maintained for a time period sufficient for them to die from that contact. Further contacting of those cells with a cytotoxic amount of an anti-cancer drug or cytotoxic conjugate enhances the death of those cancer cells. In another process, peripheral CLL cells that proliferate on contact with an immune response-enhancing-agent are contacted with a proliferation-inducing amount of such an agent.
Abstract: The present invention is directed to novel amphetamine derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to amphetamine and amphetamine metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
Type:
Grant
Filed:
April 6, 1992
Date of Patent:
November 28, 1995
Assignee:
Biosite Diagnostics Incorporated
Inventors:
Kenneth F. Buechler, Joseph B. Noar, Si S. Moi
Abstract: The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.
Type:
Grant
Filed:
April 14, 1992
Date of Patent:
November 21, 1995
Assignee:
Amergen, Inc.
Inventors:
Somesh D. Sharma, Brian R. Clark, Bernard L. Lerch